SCHEMBL3220143

SCHEMBL3220143

CS(=O)(=O)c1ccc2nn(-c3ccc4ccccc4c3)nc2c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.43
ALOX5 P09917 1/20 0.42
PTGS2 P35354 4/20 0.41
PTGS1 P23219 1/20 0.41
ALDH1A1 P00352 2/20 0.41
MAPT P10636 2/20 0.41
TSHR P16473 1/20 0.41
MAPK1 P28482 1/20 0.41
GAA P10253 2/20 0.40
NPBWR1 P48145 1/20 0.40
ACSS2 Q9NR19 1/20 0.39
HTT P42858 2/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
MAOA P21397 1/20 0.39
MAOB P27338 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3230905 0.79 MEN1 (0.50) ATMPTGS2PTGS1ALDH1A1MAPT
SCHEMBL3223168 0.78 MAPT (0.56) ATMPTGS2PTGS1ALDH1A1MAPT
SCHEMBL10330357 0.78 HPGD (0.56) ALOX5ALDH1A1MAPTGAAHTT
SCHEMBL3210223 0.76 PTGS2 (0.40) ATMALOX5PTGS2PTGS1ALDH1A1
SCHEMBL7912386 0.75 MEN1 (0.52) ALDH1A1MAPTTSHRGAACYP1A2
SCHEMBL758323 0.75 ATM (0.66) ATMPTGS2TSHRGAAL3MBTL1
SCHEMBL24458113 0.72 NPC1 (0.65) ATMPTGS2ALDH1A1MAPTGAA
SCHEMBL15624757 0.69 ATM (0.59) ATMPTGS2TSHRGAAL3MBTL1
SCHEMBL27854375 0.69 ALDH1A1 (0.54) ALDH1A1MAPTTSHRMAPK1GAA
SCHEMBL2602390 0.68 PTGS2 (0.56) ALOX5PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100168072-A1 Drug Combinations for the Treatment of Duchenne Muscular Dystrophy BIOMARIN IGA LIMITED 2010-07-01 US claimed
US-20120149741-A1 TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY BIOMARIN IGA LIMITED (BS) 2012-06-14 US disclosed
US-20100168072-A1 Drug Combinations for the Treatment of Duchenne Muscular Dystrophy BIOMARIN IGA LIMITED 2010-07-01 US disclosed
EP-2176230-A2 TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY BioMarin IGA Limited (BS) 2010-04-21 EP disclosed
EP-2170325-A2 DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY Summit Corporation Plc (GB) 2010-04-07 EP disclosed
US-20100048660-A1 TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY BIOMARIN IGA LIMITED (BS) 2010-02-25 US disclosed
WO-2009021747-A2 TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY SUMMIT CORPORATION PLC (GB) 2009-02-19 WO disclosed
WO-2009019505-A2 DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY SUMMIT CORPORATION PLC (GB) 2009-02-12 WO disclosed
EP-1986643-A1 TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY Summit Corporation Plc (GB) 2008-11-05 EP disclosed
WO-2007091107-A1 TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY SUMMIT CORPORATION PLC (GB) 2007-08-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048660-A1 TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY SMN1; SMN2, CPT1B, GYS1 ATM 1568/4885ALOX5 4110/4885PTGS2 4079/4885
US-20120149741-A1 TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY SMN1; SMN2, ACVR2B, CPT1B ATM 2063/4885ALOX5 3969/4885PTGS2 3442/4885
US-20100168072-A1 Drug Combinations for the Treatment of Duchenne Muscular Dystrophy CPT1B, PYGM, MTPN ATM 1905/4885ALOX5 2341/4885PTGS2 2866/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.